Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CANF with free AI briefings, catalyst countdowns, and dilution alerts.

CANF · Can-Fite BioPharma Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$7M Cash on Hand
8.9mo Cash Runway
Follow CANF by email Get an email when CANF reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CANF, unsubscribe in one click. Privacy

📣 What CANF Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Piclidenoson (CF101) Keratoconjunctivitis Sicca Phase 3 · NCT01235234 Completed
Methotrexate Rheumatoid Arthritis Phase 3 · NCT02647762 Terminated
Namodenoson (CF102) Hepatocellular Carcinoma Phase 3 · NCT05201404 Recruiting
CF 102 Chronic Hepatitis C Phase 1/2 · NCT00790673 Completed

Also used in these trials (approved or third-party drugs, not CANF's own candidates): Apremilast.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CANF holds $7M in cash and short-term investments and burns about $2.4M/quarter from operations, an estimated runway of 8.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CANF files for a raise →

👥 Who Owns CANF

Insiders 0% Institutions (13 holders) 2.5% Public and other holders 97.5%
HolderTypeShares% of sharesAs of
Pnina Fishman
Chief Scientific Officer, Director · +34,299 options
Insider 88 0.00% 2026-03-18
Guy Regev
Director
Insider 8 0.00% 2026-03-18

Share count 2,618,425 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CANF picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CANF and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.